HEREDITARY LEIOMYOMATOSIS & RENAL CELL CANCER

HLRCC — a hereditary cancer syndrome where renal cell carcinoma metastasizes at remarkably small sizes, making standard active surveillance protocols dangerous and requiring immediate surgical intervention for any suspicious renal lesion.

Whole genome sequencing identifies all FH (fumarate hydratase) variants — providing the molecular diagnosis that fundamentally changes renal mass management from 'watch and wait' to 'operate immediately.'

About this condition

Hereditary Leiomyomatosis and Renal Cell Cancer

Hereditary leiomyomatosis and renal cell cancer (HLRCC, Reed syndrome) is an autosomal dominant cancer predisposition syndrome caused by heterozygous pathogenic variants in FH (fumarate hydratase, chromosome 1q43). FH is a tumor suppressor functioning in the tricarboxylic acid (TCA) cycle — FH deficiency causes fumarate accumulation, which inhibits prolyl hydroxylases and stabilizes HIF (hypoxia-inducible factor), driving a pseudohypoxic oncogenic program. HLRCC produces three clinical features: cutaneous leiomyomas (painful skin nodules in ~76%), uterine leiomyomas (fibroids, often symptomatic before age 30 in ~77% of women), and renal cell cancer (~15-25% lifetime risk).

The renal cell cancer in HLRCC is type 2 papillary RCC — and it is uniquely aggressive. Unlike the indolent RCC seen in VHL disease or other hereditary RCC syndromes, HLRCC-associated RCC can metastasize when the primary tumor is only 1-2 centimeters. This biological aggressiveness fundamentally changes the management paradigm: standard active surveillance protocols for small renal masses (≤4cm, which are appropriate for most sporadic RCC) are DANGEROUS in HLRCC. Any solid renal lesion in an HLRCC patient should be considered potentially aggressive and managed with prompt surgical excision, not observation.

HLRCC is underdiagnosed because the individual features — skin bumps and uterine fibroids — are common in the general population and are often managed by dermatologists and gynecologists without considering the hereditary cancer context. The painful cutaneous leiomyomas (characteristically cold-sensitive) are the most specific clinical clue. Early-onset uterine fibroids requiring hysterectomy before age 30 should also prompt FH evaluation. Molecular FH diagnosis triggers the specific HLRCC renal surveillance protocol (annual high-quality MRI, not ultrasound) that cannot be implemented without knowing the patient carries an FH pathogenic variant.

Active surveillance of small renal masses — standard of care for most RCC — is CONTRAINDICATED in HLRCC. The aggressive biology means that even 1-2cm HLRCC tumors can metastasize. Any solid renal lesion requires prompt surgical excision.

Gene locus: FH (1q43)

Standard RCC management protocols assume indolent biology. FH-associated RCC has aggressive biology that violates this assumption. Molecular FH diagnosis triggers the surveillance and treatment protocol that prevents metastatic disease.

Standard active surveillance kills HLRCC patients — molecular FH diagnosis changes the surgical urgency for renal masses

For sporadic small renal masses (≤4cm), active surveillance with imaging follow-up is an accepted management strategy because most are low-grade and slow-growing. In HLRCC, applying this same surveillance approach to a 2cm type 2 papillary RCC risks allowing metastatic spread before the surveillance protocol triggers intervention. Multiple HLRCC patients have developed metastatic disease from primary tumors that would have been managed with surveillance under standard RCC protocols. Molecular FH diagnosis before any renal mass is detected enables the HLRCC-specific protocol: annual MRI surveillance and immediate surgery for any solid lesion.

Painful skin bumps + early fibroids = consider HLRCC. Most dermatologists and gynecologists do not make this connection

Cutaneous leiomyomas (painful, cold-sensitive skin nodules typically on the trunk and extremities) and early-onset uterine leiomyomas are individually common — but their combination, particularly with a family history of kidney cancer, should prompt FH evaluation. Many HLRCC families are identified only after a member develops metastatic RCC — by which point the cancer is often incurable. WGS performed for any indication can identify FH variants incidentally, triggering the renal surveillance program that would have detected the cancer at a curable stage.

HLRCC — a hereditary cancer syndrome where renal cell carcinoma metastasizes at remarkably small sizes, making standard active surveillance protocols dangerous and requiring immediate surgical intervention for any suspicious renal lesion.

Hereditary Leiomyomatosis and Renal Cell Cancer

Standard RCC management protocols assume indolent biology. FH-associated RCC has aggressive biology that violates this assumption. Molecular FH diagnosis triggers the surveillance and treatment protocol that prevents metastatic disease.

Standard active surveillance kills HLRCC patients — molecular FH diagnosis changes the surgical urgency for renal masses

Painful skin bumps + early fibroids = consider HLRCC. Most dermatologists and gynecologists do not make this connection

Others in Hereditary Cancer

One test. A lifetime of answers.